Skip to NavigationSkip to content

Novartis' new MS drug to cost $88,000 a year

Published on 27/03/19 at 09:46am

Paul Hudson, the CEO of Swiss firm Novartis Pharmaceuticals has said the company’s newly approved multiple sclerosis (MS) drug will cost $88,000 a year.

The drug, which won FDA approval on 26 March for patients with active secondary progressive multiple sclerosis (SPMS), is the first and only treatment to be approved in that specific indication in more than 15 years.

Mayzent is a synthetic derivative of Novartis’ Gilenya which the company has modified in an attempt to reduce side effects such as slow heart rate.

Gilenya currently generates $3.34 billion in sales for Novartis each year. However Mayzent is targeted towards older patients who have transitioned from relapsing to a state of SPMS, during which period their condition gradually deteriorates.

Sales of Mayzent are expected to reach $800 million by 2022, according to the median estimate of six analysts surveyed by Refinitiv.

At a cost of $88,000 per annum, the drug will be more expensive than Roche’s MS drug Ocrevus which costs just $65,000 a year.

“One of the most important aims of MS treatment is delaying disability progression and preserving cognition,” said Paul Hudson, Chief Executive Officer, Novartis Pharmaceuticals.

“With Mayzent, SPMS patients with active disease will have access to the first effective oral therapy directed towards disease progression, even when MS transitions to a stage where deterioration is less dependent on the usual relapse activity.”

“Mayzent is a testament to the Novartis mission to reimagine medicine. We are delighted that our ongoing commitment to stop MS has led to a much awaited treatment for these patients in need.”

Louis Goss

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches